
Quarterly report 2024-Q1
added 05-08-2024
Cerevel Therapeutics Holdings Net Debt 2011-2026 | CERE
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cerevel Therapeutics Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.6 M | 202 M | -161 M | - | - | - | - | - | -3.69 M | -3.34 M | -8.64 M | -20.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 202 M | -161 M | -4.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Adagene
ADAG
|
-71 M | $ 1.65 | 7.91 % | $ 92.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.59 | 1.99 % | $ 8.64 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 66.05 | 2.3 % | $ 8.83 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.52 | -16.3 % | $ 388 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
4.01 B | $ 184.48 | -1.67 % | $ 26.9 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 102.17 | 2.32 % | $ 27.2 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 93.52 | -1.2 % | $ 96.9 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.25 | 1.67 % | $ 9.25 B | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Bristol-Myers Squibb Company
BMY
|
37.4 B | $ 55.71 | -0.28 % | $ 113 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 207.49 | 2.22 % | $ 5 B | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Zai Lab Limited
ZLAB
|
-428 M | $ 18.37 | -0.97 % | $ 18.2 B | ||
|
Coherus BioSciences
CHRS
|
-101 M | $ 1.61 | -5.03 % | $ 152 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 10.84 | 0.46 % | $ 714 M | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 25.59 | -6.54 % | $ 1.65 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 4.22 | -4.2 % | $ 116 M | ||
|
Clearside Biomedical
CLSD
|
-27.9 M | - | - | $ 25.3 M | ||
|
Chimerix
CMRX
|
-25.8 M | - | - | $ 756 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
-121 M | $ 37.35 | -0.4 % | $ 3.86 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 23.18 | 2.02 % | $ 2.75 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-213 M | $ 55.11 | 3.49 % | $ 4.45 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-74.6 M | $ 55.17 | 2.47 % | $ 4.65 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
17.7 M | $ 3.53 | -5.75 % | $ 231 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 29.43 | 6.09 % | $ 1.43 B |